The difficulty in alleviating cachexia by using monotherapies against pro-inflammatory humoral factors such as TNFα and IL-6 has been attributed to the redundancy of downstream effectors of these cytokines and the presence of multiple signaling pathways sufficient to induce atrophy. The gene discussed is TNF; the disease is Cachexia.